Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes

Renalytix plc (LSE: RENX; OTCQB: RNLXY), a precision‑medicine diagnostics company focused on kidney health and the developer of kidneyintelX.dkd, announced on 18 November 2025 that new pivotal data have been published in Diabetes Care — recognised as the top‑ranked global diabetes journal of the American Diabetes Association. The manuscript, titled “Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association with Kidney Outcomes in the CANVAS and CREDENCE Trials,” draws on data from 2,954 patients enrolled in the landmark CANVAS and CREDENCE trials — representing the full intended‑use population for the kidneyintelX.dkd test. Key findings include: The kidneyintelX.dkd test significantly improved risk stratification across all categories of the Kidney Disease: Improving Global Outcomes (KDIGO) guideline, enabling more accurate assessment of progression risk in chronic kidney disease (CKD) and the likelihood of kidney failure. Among patients classified as moderate or high risk by the test, those treated with frontline SGLT2 inhibitors demonstrated a significant reduction in kidneyintelX.dkd risk levels at one year — with high‑risk patients being twice as likely to show risk improvement versus untreated patients. According to Associate Professor Brendon Neuen of The George Institute for Global Health in Sydney – who co‑authored the study – the time is ripe for “risk‑based implementation” in CKD care. He says that incorporating novel biomarkers, as done in kidneyintelX.dkd, “holds strong promise to guide risk‑based care” and that these new data provide “a compelling example” of building on established clinical parameters to deliver personalised care and reduce adverse outcomes. In parallel with the publication, Renalytix presented three new abstracts at ASN Kidney Week 2025 (Houston, Nov 5–9) showcasing the device’s real‑world implementation, clinical utility, and performance benefits in head‑to‑head comparisons (including vs. the Kidney Failure Risk Equation — KFRE). For example, in community practice, 87 % of patients said the test improved their understanding of kidney risk; 86 % of physicians reported the test influenced care decisions. With CKD affecting some 850 million individuals globally (and over 35 million adults in the US, more than 90% of whom are unaware of their condition) and US Medicare spending more than US$130 billion annually on kidney disease and kidney failure, the need for better prognostic tools is pressing. Renalytix is an AI‑enabled in‑vitro diagnostics company, and kidneyintelX.dkd is FDA‑approved and commercially available in the US with Medicare reimbursement. #kidneyhealth #precisionmedicine #CKD #diabetescare #SlimScan #GrowthStocks #CANSLIM